A Primate Model for Viral Hemorrhagic Fever

2017 ◽  
pp. 279-290 ◽  
Author(s):  
Maria S. Salvato ◽  
Igor S. Lukashevich ◽  
Yida Yang ◽  
Sandra Medina-Moreno ◽  
Mahmoud Djavani ◽  
...  
Keyword(s):  
Hemorrhagic Fever ◽  
Viral Hemorrhagic Fever ◽  
Primate Model

scholarly journals Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus

2007 ◽  
Vol 81 (12) ◽  
pp. 6379-6388 ◽  
Author(s):  
Alexander Bukreyev ◽  
Pierre E. Rollin ◽  
Mallory K. Tate ◽  
Lijuan Yang ◽  
Sherif R. Zaki ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Ebola Virus ◽  
Protective Efficacy ◽  
Hemorrhagic Fever ◽  
Surface Glycoprotein ◽  
Respiratory Pathogen ◽  
Viral Hemorrhagic Fever ◽  
Primate Model ◽  
Challenge Virus ◽  
Virus Challenge

ABSTRACT Ebola virus causes outbreaks of severe viral hemorrhagic fever with high mortality in humans. The virus is highly contagious and can be transmitted by contact and by the aerosol route. These features make Ebola virus a potential weapon for bioterrorism and biological warfare. Therefore, a vaccine that induces both systemic and local immune responses in the respiratory tract would be highly beneficial. We evaluated a common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector against Ebola virus. HPIV3 recombinants expressing the Ebola virus (Zaire species) surface glycoprotein (GP) alone or in combination with the nucleocapsid protein NP or with the cytokine adjuvant granulocyte-macrophage colony-stimulating factor were administered by the respiratory route to rhesus monkeys—in which HPIV3 infection is mild and asymptomatic—and were evaluated for immunogenicity and protective efficacy against a highly lethal intraperitoneal challenge with Ebola virus. A single immunization with any construct expressing GP was moderately immunogenic against Ebola virus and protected 88% of the animals against severe hemorrhagic fever and death caused by Ebola virus. Two doses were highly immunogenic, and all of the animals survived challenge and were free of signs of disease and of detectable Ebola virus challenge virus. These data illustrate the feasibility of immunization via the respiratory tract against the hemorrhagic fever caused by Ebola virus. To our knowledge, this is the first study in which topical immunization through respiratory tract achieved prevention of a viral hemorrhagic fever infection in a primate model.

scholarly journals Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus

2004 ◽  
Vol 4 (1) ◽  
Author(s):  
Fatih M Uckun ◽  
Alexander S Petkevich ◽  
Alexei O Vassilev ◽  
Heather E Tibbles ◽  
Leonid Titov
Keyword(s):  
Mouse Model ◽  
Hemorrhagic Fever ◽  
Lassa Virus ◽  
Viral Hemorrhagic Fever ◽  
Experimental Mouse Model ◽  
Experimental Mouse

Dengue Fever: A Viral Hemorrhagic Fever of Global Concern

2020 ◽  
pp. 99-163
Author(s):  
Bennet Angel ◽  
Neelam Yadav ◽  
Jagriti Narang ◽  
Annette Angel ◽  
Vinod Joshi
Keyword(s):  
Dengue Fever ◽  
Hemorrhagic Fever ◽  
Viral Hemorrhagic Fever ◽  
Global Concern

“STUDY OF SERUM AMINOTRANSFERASE LEVELS IN DENGUE FEVER”

2021 ◽  
pp. 15-16
Author(s):  
Tabitha R J Chandrika ◽  
Chennakesavulu Dara ◽  
Gandhi Parise ◽  
.Phani Krishna Telluri
Keyword(s):  
Public Health ◽  
Dengue Infection ◽  
Hemorrhagic Fever ◽  
South East Asia ◽  
Adverse Consequence ◽  
Viral Hemorrhagic Fever ◽  
Serum Aminotransferase ◽  
Hepatic Involvement ◽  
Wide Geographical Distribution ◽  
The Right

Dengue infection, an arthropod-borne viral hemorrhagic fever, continues to be a major challenge to public health, especially in South-East Asia. It has a wide geographical distribution and can present with a diverse clinical spectrum. The liver dysfunction could be a direct viral effect or an adverse consequence of dysregulated host immune response against the virus. Hepatic involvement can be characterized by manifestations of acute hepatitis, with pain in the right hypochondrium, hepatomegaly, jaundice, and raised aminotransferase levels. Several outbreaks of dengue infection have been reported from India. However, large clinical studies documenting hepatic involvement in dengue infection, especially in adults, are scarce.

Outbreak investigation and intervention measures following viral hemorrhagic fever in rural Kutch (Gujarat)

2013 ◽  
Vol 2 (3) ◽  
pp. 189 ◽  
Author(s):  
KishorM Dhaduk ◽  
KapiilM Gandha ◽  
NareshR Makwana ◽  
DipeshV Parmar ◽  
SumitV Unadkat ◽  
...  
Keyword(s):  
Hemorrhagic Fever ◽  
Outbreak Investigation ◽  
Viral Hemorrhagic Fever ◽  
Intervention Measures

scholarly journals Immune Modulation and Immune-Mediated Pathogenesis of Emerging Tickborne Banyangviruses

Vaccines ◽  
2019 ◽  
Vol 7 (4) ◽  
pp. 125 ◽  
Author(s):  
Mendoza ◽  
Ebihara ◽  
Yamaoka
Keyword(s):  
Immune Modulation ◽  
Severe Disease ◽  
Hemorrhagic Fever ◽  
Mortality Rates ◽  
Viral Hemorrhagic Fever ◽  
New Class ◽  
Viral Immune Evasion ◽  
Immune Mediated ◽  
Significant Disease ◽  
Severe Fever

In the last decade, the emergence of several, novel tickborne viruses have caused significant disease in humans. Of interest are the tickborne banyangviruses: Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV), and Guertu virus (GTV). SFTSV and HRTV infection in humans cause viral hemorrhagic fever-like disease leading to mortality rates ranging from 6–30% of the cases. The systemic inflammatory response syndrome (SIRS) associated with SFTSV infection is hypothesized to contribute significantly to pathology seen in patients. Despite the severe disease caused by HRTV and SFTSV, there are no approved therapeutics or vaccines. Investigation of the immune response during and following infection is critical to the generation of fully protective vaccines and/or supportive treatments, and overall understanding of viral immune evasion mechanisms may aid in the development of a new class of therapeutics.

Implementation of the Canadian Contingency Plan for a Case of Suspected Viral Hemorrhagic Fever

2003 ◽  
Vol 24 (4) ◽  
pp. 280-283 ◽  
Author(s):  
Mark Loeb ◽  
Douglas MacPherson ◽  
Michele Barton ◽  
Jan Olde
Keyword(s):  
High Risk ◽  
Tertiary Care ◽  
Hemorrhagic Fever ◽  
Internal Communication ◽  
Contact Tracing ◽  
Suspected Case ◽  
Viral Hemorrhagic Fever ◽  
Laboratory Equipment ◽  
Contingency Plan ◽  
Close Contacts

AbstractObjective:To describe the implementation of the Canadian contingency plan for viral hemorrhagic fever (VHF) in response to a suspected case.Setting:A 300-bed, tertiary-care, university-affiliated hospital.Participants:A 32-year-old Congolese woman admitted to the hospital with suspected VHF in February 2001. Contact evaluation included hospital healthcare workers and laboratory staff.Intervention:Enhanced isolation precautions were implemented in the patient care setting to prevent nosocomial transmission. Contact tracing and evaluation of close and high-risk contacts with symptoms was conducted. Laboratory precautions included barrier precautions and diversion of specimens. Communication occurred to both hospital employees and the media.Results:Three high-risk contacts, 13 close contacts, and 60 casual contacts were identified. Two close contacts became symptomatic and required evaluation. Challenging process issues included tracing of laboratory specimens, decontamination of laboratory equipment, and internal and external communication. After 5 days, a transmissible VHF of public health consequence was ruled out in the index case.Conclusion:Contingency plans for VHF can be implemented in an efficient and feasible manner. Contact tracing, laboratory issues, internal communication, and media interest can be anticipated to be the key challenges.

Viral hemorrhagic fever viruses

2013 ◽  
Vol 59 (12) ◽  
pp. 410-425 ◽  
Author(s):  
Robin B. McFee
Keyword(s):  
Hemorrhagic Fever ◽  
Viral Hemorrhagic Fever
Sign in / Sign up

Export Citation Format

Share Document